Exact Sciences (EXAS)
(Real Time Quote from BATS)
$41.33 USD
-0.55 (-1.31%)
Updated Jun 17, 2024 12:10 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 161 - 180 ( 366 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q15 Volume Outlook Light Despite Positive Early Metrics
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
4Q14 Preview - Expecting Healthy Test Ramp - Refining Our Street-High Model Lower for Medicare Advantage, Timing and Precedents - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Updating Model - Early Commercial Traction Positive
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare: 4Q 2014: Quarterly Medical Technology Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Preannouncement Watch - Look for Med Tech News into Next Week?s JPM Conference.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Still Early for Sales, But Initial Dr. Sign-ups & Post CMS Order Acceleration Seems Good - Test Compliance Unknown - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Preview - Early Days for Revenue Collection - Volume Ramp, In-Network Contracting & Opex in Focus - Reaffirm N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q 2014: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upping PT to $19 from $14 Post Prelim CMS Pricing Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
CMS Reimbursement Likely at $502 -Significant Win; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Receives Positive Recommendation for a National Coverage Decision from CMS
Provider: The Benchmark Company
Analyst: WALD J